 You know, I've never gone back, and I don't even know. So this MORF is being bought for $2.8 billion. They have no sales right now. It's in development. Eli Lilly, $2.8 billion in cash, and, of course, they've got tons of cash. I've never gone back on all these no-sale biotechs being bought, and there's been, I'm going to say, a couple of dozen in the last couple of decades.